Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Melanoma × Glucose × Clear all

Phase

Phase NA 1 Phase 3 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Ovarian Neoplasms 2 Neoplasm Metastasis 2 Fallopian Tube Neoplasms 2 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Peritoneal Neoplasms 1 Melanoma 1 Limited Stage Small Cell Lung Cancer 1 Head and Neck Neoplasms 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Dacarbazine 24 Nivolumab 20 pembrolizumab 17 Ipilimumab 15 Interferon-alpha 10 trametinib 8 dabrafenib 7 aldesleukin 7 Vemurafenib 7 Temozolomide 7 Introns 6 Interferon alpha-2 6 Interleukin-2 5 Cisplatin 5 binimetinib 4 Radiotherapy 4 Chemotherapy, Adjuvant 4 encorafenib 3 cobimetinib 3 cemiplimab 3 Vinblastine 3 Specimen Handling 3 Sodium Chloride 3 Radiosurgery 3 Paclitaxel 3 Opdualag 3 Melphalan 3 Magnetic Resonance Spectroscopy 3 CTLA-4 Antigen 3 technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05933577 2025-09-24

V940-001

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡